CD19 and acute lymphoblastic leukemia: Day +30 BMA post-alloSCT showed CR with low-level MRD (5 x 10-4) and, on day +60 post-alloSCT, the patient relapsed with CD19-negative B-ALL and passed away for disease progression on day +90.